Ultragenyx Pharmaceutical Inc.NASDAQ: RARE

Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)

· Issued by Ultragenyx Pharmaceutical Inc.

On 6ix: 6ix.com/news/ultragenyx-and-mereo-biopharma-announce-new-phase-2-data-phase-2-3-orbit-study

Watch Ultragenyx Pharmaceutical's latest callUltragenyx Pharmaceutical (NASDAQ:RARE) Q2 2026 Earnings Call · Replay · Aug 4Read the transcript of Ultragenyx Pharmaceutical (NASDAQ:RARE) Q2 2026 Earnings Call

14-month data show treatment with setrusumab resulted in a large, sustained 67% reduction in annualized fracture rate and persistent median annualized fracture rate of 0.00 (p=0.0014)

Treatment resulted in continued, substantial improvements in bone mineral density (BMD) with a mean increase from baseline of 22% (p

Ultragenyx Pharmaceutical Inc. on 6ix

Story so far

Earlier from Ultragenyx Pharmaceutical

Later from Ultragenyx Pharmaceutical

All Ultragenyx Pharmaceutical news releases